

Figure 10 is a flowchart of the synthesis of the expression of synthetic cyanovirin genes as described in Example 3.

Figure 11 is a flowchart of the purification of recombinant cyanovirin proteins as described in Example 4.--

Page 15, line 25, after "cells" insert --)---

Page 21, line 35, change "8, 9 and 10," to --5A-6D,--

Page 22, line 5, change "6 and 7)," to --5A-6D),--

Page 36, line 22, change "1D" to --1C--.

Page 36, line 35, change "1E" to --1D--.

Page 37, lines 1-3, delete "Results from the nonreduced HPLC fractions are shown in Figure 1C and those from the reduced HPLC fractions are shown in Figure 1F."

Page 37, line 17, delete "(as shown in Figure 1C)".

Page 37, line 22, change "1D" to --1C--.

Page 37, line 25, change "1E" to --1D--.

Page 37, line 28, delete "(Figure 1C)".

Page 37, line 31, delete "(Figure 1F)".

Page 38, lines 24-35, change "as follows:" to -- depicted in Figure 9--.

Please delete the flowchart on page 39.

Page 42, line 19, change "individual in the following flow chart" to -- depicted in Figure 10,--.

Please delete the flowchart on page 43.

Page 44, line 36, change "follows:" to -- depicted in Figure 11,--.

Please delete the flowchart on page 45.

Page 46, line 33, change "1.2x12<sup>5</sup>" to -- 1.2x10<sup>5</sup>--.

Page 50, line 9, change "7" to --7A--.

Page 50, line 17, change "(linegraphs)" to --(Figure 7A)--.

Page 50, line 17, change "inset)" to --Figure 7B)--.

Page 50, line 22, change "7)" to --7B)--.

Page 51, line 3, change "8A" to -- 8--.

Page 51, lines 22 and 23, change "Figure 8B is a" to --A--.

Page 51, line 24, change ", which shows" to --showed--.

#### IN THE CLAIMS:

Please cancel claims 1-19.

Please add the following new claims:

*Sub: C*  
~~20. A method of inhibiting therapeutically or prophylactically a viral infection of a host, which method comprises administering to the host an antiviral effective amount of an isolated and purified antiviral agent selected from the group consisting of (1) an antiviral protein, (2) an antiviral peptide, (3) an antiviral protein conjugate, and (4) an antiviral peptide conjugate, wherein said antiviral protein or antiviral peptide is encoded by an isolated and purified nucleic acid molecule encoding at least nine contiguous amino acids of SEQ ID NO: 2, wherein said at least nine contiguous amino acids of SEQ ID NO: 2 has antiviral activity, whereupon administration of said antiviral effective amount of said antiviral agent, said viral infection of said host is inhibited.~~

*Sub: B*  
~~21. The method of claim 20, wherein said antiviral protein comprises the amino acid sequence of SEQ ID NO: 2.~~

*Sub: B*  
~~22. The method of claim 20, wherein said antiviral protein conjugate or said antiviral peptide conjugate comprises (i) at least nine contiguous amino acids of SEQ ID NO: 2, wherein said at least nine contiguous amino acids of SEQ ID NO: 2 has antiviral activity, and (ii) an isolated and purified viral envelope glycoprotein.~~

*Sub: B*  
~~23. The method of claim 22, wherein said antiviral protein comprises the amino acid sequence of SEQ ID NO: 2.~~

*Sub: B*  
~~24. The method of claim 22, wherein said isolated and purified viral envelope glycoprotein is an isolated and purified retroviral envelope glycoprotein.~~

*Sub: B*  
~~25. The method of claim 24, wherein said isolated and purified retroviral envelope glycoprotein is an isolated and purified immunodeficiency viral envelope glycoprotein.~~

*Sub: B*  
~~26. The method of claim 25, wherein said isolated and purified immunodeficiency viral envelope glycoprotein is an isolated and purified viral envelope glycoprotein of HIV-1 or HIV-2.~~

*Sub: B*  
~~27. The method of claim 26, wherein said isolated and purified viral envelope glycoprotein of HIV-1 or HIV-2 comprises gp120.~~